FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Esophageal cancer (CA) diagnosis and staging rely on imaging modalities.
• Computed tomography (CT) is a standard tool, but its accuracy in esophageal CA can be limited.
• Evaluating the added clinical utility of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) over CT is crucial for patient management.

Purpose of the Study:

• To assess the clinical utility of FDG-PET in patients with esophageal cancer.
• To determine the incremental value of FDG-PET compared to CT scans in esophageal CA evaluation.

Main Methods:

• Retrospective review of 151 FDG-PET and CT scan reports from 109 patients with biopsy-proven esophageal CA.
• FDG-PET images acquired 45-60 minutes post-injection of 370 MBq F-18-FDG.
• Diagnosis confirmed by histology (91.3%) or clinical follow-up (>6 months).

Main Results:

• FDG-PET demonstrated higher accuracy (86%) than CT (73%) for esophageal CA evaluation (P=0.0002).
• FDG-PET sensitivity was 80% and specificity 95%, compared to 68% and 81% for CT.
• PET detected 24 additional lesions in 20% of patients, leading to management changes in 14%.

Conclusions:

• FDG-PET is a more accurate imaging modality than CT for esophageal cancer staging and follow-up.
• FDG-PET provides significant incremental information, influencing clinical management decisions in a notable percentage of patients.
• The findings support the integration of FDG-PET into the diagnostic workup of esophageal cancer.